Wells Fargo & Company Denali Therapeutics Inc. Put Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding DNLI
# of Institutions
221Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO13.8MShares$336 Million0.25% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$297 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$267 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$202 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$154 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.27B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...